Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human trial of HemaXellerate-I in patients with bone marrow suppression

Next Previous
Trial Profile

First-in-human trial of HemaXellerate-I in patients with bone marrow suppression

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HemaXellerate I (Primary)
  • Indications Bone marrow disorders
  • Focus Adverse reactions; First in man; Proof of concept

Most Recent Events

  • 24 Oct 2016 Final clinical data on their first 5 patients published in Regen BioPharma media release.
  • 16 Aug 2016 Updated interim results (n=5) published in a Regen BioPharma Inc media release.
  • 11 May 2016 According to Regen media release, the Company intends to amend its previously submitted Investigational New Drug Application for HemaXellerate in order that Regen may obtain consent from the United States Food and Drug Administration (FDA) to pursue this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top